Figure 1 | Scientific Reports

Figure 1

From: Humoral response to SARS-CoV-2 mRNA vaccine on in ABO blood type incompatible kidney transplant recipients treated with low-dose rituximab

Figure 1

The proportion of eligible participants and trends in anti-SARS-CoV-2 IgG S antibody titers after the mRNA vaccination. (A) The proportion of eligible participants who had received the SARS-CoV-2 mRNA vaccines. (B) Trends in anti-SARS-CoV-2 IgG S antibody titers after the mRNA vaccination in the control group (n = 154). (C) Trends in anti-SARS-CoV-2 IgG S antibody titers after the mRNA vaccination in kidney transplant recipients who had received the mRNA vaccine before kidney transplantation (n = 122). SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, S spike, IGG immunoglobulin G.

Back to article page